CytomX Therapeutics-JPM-202401.pdf

1、A Multi-Modality ProbodyTherapeutic Pipeline to Address Major Unmet Needs in OncologyJanuary 2024Forward-Looking StatementsThis presentation may contain projections and other forward-looking statements regarding future events.All statements other than statements of historical facts contained in this

2、 presentation,including statements regarding our future financial condition,technology platform,development strategy,prospective products,preclinical and clinical pipeline and milestones,regulatory objectives,expected payments from and outcomes of collaborations,and likelihood of success,are forward

3、-looking statements.Such statements are predictions only and involve known and unknown risks,uncertainties and other important factors that may cause our actual results,performance or achievements to be materially different from any future results,performance or achievements expressed or implied by

4、the forward-looking statements.These risks and uncertainties include,among others,the costs,timing and results of preclinical studies and clinical trials and other development activities;the uncertainties inherent in the initiation and enrollment of clinical trials;the uncertainties associated with

5、the COVD-19 pandemic;expectations of expanding on-going clinical trials;availability and timing of data from clinical trials;the unpredictability of the duration and results of regulatory review;market acceptance for approved products and innovative therapeutic treatments;competition;the potential n

6、ot to receive partnership milestone,profit sharing or royalty payments;the possible impairment of or inability to obtain intellectual property rights;and possible safety or efficacy concerns,general business,financial and accounting risks and litigation.Because forward-looking statements are inheren